Diagnostic accuracy of apoptosis markers in non-alcoholic fatty liver disease in children
DOI:
https://doi.org/10.14739/2310-1237.2020.3.221867Keywords:
cytokeratin-18, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, diagnostic accuracy, childrenAbstract
Introduction. Non-alcoholic fatty liver disease (NAFLD) is recognized as one of the most common chronic liver diseases in children and adults worldwide. Early diagnosis of rapidly progressive forms of NAFLD – non-alcoholic steatohepatitis (NASH) – is crucial, because therapeutic intervention in the early disease stages creates unique opportunities for the reversal of pathological changes and restoration of liver structure and function. Despite the variety of currently available diagnostic scales and indices, laboratory diagnosis of NAFLD in children requires new non-invasive tests and their validation.
Aim: To investigate the differences of cytokeratin-18 (CK18) and the combined marker MACK-3 levels in children with nonalcoholic steatohepatitis (NASH), simple hepatic steatosis, overweight and obese children without hepatic steatosis.
Materials and methods. The study included 170 patients aged 6 to 17 years. The mean age of patients was (12.15 ± 2.51) years. According to the presence of steatosis, steatohepatitis, overweight and obesity, patients were divided into 4 groups: the 1st group consisted of 37 patients with NASH, the 2nd group – 53 patients with simple steatosis, the 3rd group – 65 overweight and obese patients without hepatic steatosis, the 4th group (control) – 15 patients with normal weight without steatosis. Biochemical hepatogram, carbohydrate metabolism investigation, as well as CK18 enzyme-linked immunosorbent assay, were conducted with the MACK-3 calculation.
Results. The average level of CK18 in children with NASH increased by 1.6 times (P <0.05) compared with children of the control group. The median CK18 level in patients with NASH was by 1.6 times (P < 0.05) and 2.0 times (P < 0.05) higher than in groups 2 and 3, respectively. T he threshold level of CK18 for the diagnosis of NASH was 87.4 U/l: its sensitivity was 81.8 %, specificity 70 %, AUROC 0.736 (P ˂ 0.05). Calculated index MACK-3 revealed a significant increase in children with NASH compared with other groups (P < 0,05). Threshold level of MACK-3 for the diagnosis of NASH was 0.053: sensitivity – 90.9 %, specificity – 81.6 %, AUROC 0.958 (P ˂ 0.05).
Conclusions. Thus, in children with NASH, a significant increase in the CK18 level was found, which can be used for early non-invasive diagnosis of NASH in children. The advantage of the calculated index MACK-3 is the increase in diagnostic accuracy and the possibility of its use to stratify the risk of the progressive course of NAFLD, which will streamline the selection of patients for active therapeutic intervention.
References
Mann, J. P., Vreugdenhil, A., Socha, P., Jańczyk, W., Baumann, U., Rajwal, S., … Anstee, Q. M. (2018). European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary clinical trials, 75, 67-71. https://doi.org/10.1016/j.cct.2018.11.003
Selvakumar, P., Kabbany, M. N., Nobili, V., & Alkhouri, N. (2017). Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications. Pediatric clinics of North America, 64(3), 659-675. https://doi.org/10.1016/j.pcl.2017.01.008
Ko J. S. (2019). New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatric gastroenterology, hepatology & nutrition, 22(6), 501-510. https://doi.org/10.5223/pghn.2019.22.6.501
Mandelia, C., Kabbany, M. N., Conjeevaram Selvakumar, P. K., & Alkhouri, N. (2018). The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. Biomarkers in medicine, 12(3), 265-273. https://doi.org/10.2217/bmm-2017-0038
Goyal, N. P., & Schwimmer, J. B. (2016). The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease. Clinics in liver disease, 20(2), 325-338. https://doi.org/10.1016/j.cld.2015.10.003
Vos, M. B., Abrams, S. H., Barlow, S. E., Caprio, S., Daniels, S. R., Kohli, R., … Xanthakos, S. A. (2017). NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of pediatric gastroenterology and nutrition, 64(2), 319-334. https://doi.org/10.1097/MPG.0000000000001482
Nobili, V., Alisi, A., Valenti, L., Miele, L., Feldstein, A. E., & Alkhouri, N. (2019). NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature reviews. Gastroenterology & hepatology, 16(9), 517-530. https://doi.org/10.1038/s41575-019-0169-z
Draijer, L., Benninga, M., & Koot, B. (2019). Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert review of gastroenterology & hepatology, 13(5), 447-461. https://doi.org/10.1080/17474124.2019.1595589
Feldstein, A. E., Wieckowska, A., Lopez, A. R., Liu, Y. C., Zein, N. N., & McCullough, A. J. (2009). Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology, 50(4), 1072-1078. https://doi.org/10.1002/hep.23050
Fitzpatrick, E., Mitry, R. R., Quaglia, A., Hussain, M. J., DeBruyne, R., & Dhawan, A. (2010). Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. Journal of pediatric gastroenterology and nutrition, 51(4), 500-506. https://doi.org/10.1097/MPG.0b013e3181e376be
Younossi, Z. M., Jarrar, M., Nugent, C., Randhawa, M., Afendy, M., Stepanova, M., Rafiq, N., Goodman, Z., Chandhoke, V., & Baranova, A. (2008). A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obesity surgery, 18(11), 1430-1437. https://doi.org/10.1007/s11695-008-9506-y
Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., Louden, C., Goros, M., & Tio, F. (2014). Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of hepatology, 60(1), 167-174. https://doi.org/10.1016/j.jhep.2013.07.042
Boursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., … Francque, S. (2018). Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Alimentary pharmacology & therapeutics, 47(10), 1387-1396. https://doi.org/10.1111/apt.14621
de Lédinghen, V., Vergniol, J., Foucher, J., Merrouche, W., & le Bail, B. (2012). Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver international, 32(6), 911-918. https://doi.org/10.1111/j.1478-3231.2012.02820.x
Desai, N. K., Harney, S., Raza, R., Al-Ibraheemi, A., Shillingford, N., Mitchell, P. D., & Jonas, M. M. (2016). Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients. The Journal of pediatrics, 173, 160-164.e1. https://doi.org/10.1016/j.jpeds.2016.03.021
Chuah, K. H., Wan Yusoff, W., Sthaneshwar, P., Nik Mustapha, N. R., Mahadeva, S., & Chan, W. K. (2019). MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. Liver international, 39(7), 1315-1324. https://doi.org/10.1111/liv.14084
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011). Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of medicine, 43(8), 617-649. https://doi.org/10.3109/07853890.2010.518623
He, L., Deng, L., Zhang, Q., Guo, J., Zhou, J., Song, W., & Yuan, F. (2017). Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. BioMed research international, 2017, 9729107. https://doi.org/10.1155/2017/9729107
Darweesh, S. K., AbdElAziz, R. A., Abd-ElFatah, D. S., AbdElazim, N. A., Fathi, S. A., Attia, D., & AbdAllah, M. (2019). Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. European journal of gastroenterology & hepatology, 31(5), 633-641. https://doi.org/10.1097/MEG.0000000000001385
Safarian, M., Mohammadpour, S., Shafiee, M., Ganji, A., Soleimani, A., Nematy, M., & Bahari, A. (2019). Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. Diabetes & metabolic syndrome, 13(2), 989-994. https://doi.org/10.1016/j.dsx.2019.01.005
Tamimi, T. I., Elgouhari, H. M., Alkhouri, N., Yerian, L. M., Berk, M. P., Lopez, R., Schauer, P. R., Zein, N. N., & Feldstein, A. E. (2011). An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Journal of hepatology, 54(6), 1224-1229. https://doi.org/10.1016/j.jhep.2010.08.023
Younossi, Z. M., Page, S., Rafiq, N., Birerdinc, A., Stepanova, M., Hossain, N., Afendy, A., Younoszai, Z., Goodman, Z., & Baranova, A. (2011). A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obesity surgery, 21(4), 431-439. https://doi.org/10.1007/s11695-010-0204-1
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., Haflidadottir, S., & Bendtsen, F. (2015). Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 149(2), 389-397.e10. https://doi.org/10.1053/j.gastro.2015.04.043
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
